NASDAQ:HALOHalozyme Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $16.68 +0.43 (+2.65 %) (As of 04/6/2020 09:37 AM ET) Add Compare Share Today's Range$16.51Now: $16.68▼$16.8150-Day Range$13.88MA: $18.77▼$21.8352-Week Range$12.71Now: $16.68▼$22.06Volume14,441 shsAverage Volume2.13 million shsMarket Capitalization$2.30 billionP/E RatioN/ADividend YieldN/ABeta1.71 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; and ARGENX BVBA. The company was founded in 1998 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 4.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.33, Halozyme Therapeutics has a potential upside of 51.9% from its current price of $16.68.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesHalozyme Therapeutics has received 428 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHalozyme Therapeutics has received 387 “underperform” votes. (Add your “underperform” vote.)Community SentimentHalozyme Therapeutics has received 52.52% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote “Outperform” if you believe HALO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $748,911.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.60% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions91.73% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 125.40% in the coming year, from $0.63 to $1.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is -33.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is -33.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 26.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.58 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:HALO Previous Symbol CUSIP40637H10 CIK1159036 Webhttp://www.halozyme.com/ Phone858-794-8889Debt Debt-to-Equity Ratio4.17 Current Ratio6.35 Quick Ratio6.00Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio26.48 P/E GrowthN/A Sales & Book Value Annual Sales$195.99 million Price / Sales11.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book26.48Profitability EPS (Most Recent Fiscal Year)($0.50) Net Income$-72,240,000.00 Net Margins-36.86% Return on Equity-33.71% Return on Assets-16.20%Miscellaneous Employees281 Outstanding Shares138,070,000Market Cap$2.30 billion Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive HALO News and Ratings via Email Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HALO Rates by TradingView Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions How has Halozyme Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Halozyme Therapeutics' stock was trading at $18.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, HALO stock has decreased by 8.5% and is now trading at $16.68. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Halozyme Therapeutics? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Halozyme Therapeutics. When is Halozyme Therapeutics' next earnings date? Halozyme Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Halozyme Therapeutics. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings data on Monday, February, 24th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by $0.06. The biopharmaceutical company had revenue of $53.70 million for the quarter, compared to analysts' expectations of $55.69 million. Halozyme Therapeutics had a negative return on equity of 33.71% and a negative net margin of 36.86%. The firm's revenue for the quarter was down 10.8% on a year-over-year basis. During the same period last year, the firm earned ($0.01) EPS. View Halozyme Therapeutics' earnings history. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics issued an update on its FY20 earnings guidance on Monday, February, 24th. The company provided EPS guidance of $0.60-0.75 for the period, compared to the Thomson Reuters consensus estimate of $0.59. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.15 million. What price target have analysts set for HALO? 6 Wall Street analysts have issued 1-year price targets for Halozyme Therapeutics' shares. Their forecasts range from $20.00 to $35.00. On average, they expect Halozyme Therapeutics' share price to reach $25.33 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price. View analysts' price targets for Halozyme Therapeutics. What are Wall Street analysts saying about Halozyme Therapeutics stock? Here are some recent quotes from research analysts about Halozyme Therapeutics stock: 1. According to Zacks Investment Research, "Halozyme has promising collaboration deals related to its ENHANZE technology with several small and large pharma companies. These deals generate the majority of revenues for the company. Blockbuster drugs like Herceptin and Rituxan use ENHANZE for subcutaneous administration, which boosts Halozyme’s royalties. Development of subcutaneous formulation of another blockbuster drug, Darzalex is encouraging. Restructuring initiatives following failure of PEGPH20 is also encouraging. Halozyme’s shares have outperformed the industry so far this year. However, the company’s dependence on collaboration partners for revenues remains a concern. Rising competition for partnered drugs is also a concern. Estimates have been stable ahead of Q3 earnings. The company has a positive record of earnings surprise in the recent quarters." (11/7/2019) 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $24 PT per share on HALO. Halozyme reported 1Q19 revenues of $57M, which were below our and FactSet consensus estimates of $62M and $69M, respectively. Additionally, the company ended 1Q19 with cash of ~$329M, and we model current cash and projected ENHANZE royalties to fund HALO through key value-creating milestones. During 1Q19, royalty revenues declined by 14% YoY, mainly due to lower sales of Herceptin SC in Europe, which were partially offset by higher sales of RITUXAN HYCELA versus 1Q18." (5/8/2019) Has Halozyme Therapeutics been receiving favorable news coverage? News articles about HALO stock have trended very negative on Monday, InfoTrie reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Halozyme Therapeutics earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutHalozyme Therapeutics. Are investors shorting Halozyme Therapeutics? Halozyme Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 13,870,000 shares, an increase of 7.9% from the February 13th total of 12,850,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is presently 8.8 days. Currently, 10.7% of the company's shares are short sold. View Halozyme Therapeutics' Current Options Chain. Who are some of Halozyme Therapeutics' key competitors? Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN). What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW). Who are Halozyme Therapeutics' key executives? Halozyme Therapeutics' management team includes the following people: Dr. Helen I. Torley, Pres, CEO & Director (Age 56)Ms. Laurie D. Stelzer, Sr. VP & CFO (Age 51)Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel & Corp. Sec. (Age 62)Dr. Dimitrios Chondros, Chief Medical Officer & Sr. VP (Age 54)Mr. Benjamin J. Hickey, Sr. VP & Chief Commercial Officer (Age 44) What is Halozyme Therapeutics' stock symbol? Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO." How do I buy shares of Halozyme Therapeutics? Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Halozyme Therapeutics' stock price today? One share of HALO stock can currently be purchased for approximately $16.68. How big of a company is Halozyme Therapeutics? Halozyme Therapeutics has a market capitalization of $2.30 billion and generates $195.99 million in revenue each year. The biopharmaceutical company earns $-72,240,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe. View additional information about Halozyme Therapeutics. What is Halozyme Therapeutics' official website? The official website for Halozyme Therapeutics is http://www.halozyme.com/. How can I contact Halozyme Therapeutics? Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected] This page was last updated on 4/6/2020 by MarketBeat.com StaffFeatured Article: The Role of a Fiduciary and Individual Investors
